Skip to Content

LivaNova PLC LIVN Stock Quote

| Rating as of


Last close prices updated as of Jan 31, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 55
  • Sector Healthcare
  • Industry Medical Devices
  • Investment Style Small Blend
  • Day Range 55.16  –  56.24
  • Year Range 41.82  –  88.00
  • Market Cap 3.0080 Bil
  • Volume / Avg 384,279.0 /  427,013.2
  • Price / Sales 2.89
  • Price / Book 2.57
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis LIVN

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


LivaNova’s Leadership in Vagus Nerve Stimulation Supports Its Narrow Moat

Debbie S. Wang Senior Equity Analyst

Business Strategy and Outlook

| Debbie Wang |

As a midsize medical device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable, and with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal R&D, potentially augmented with acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics LIVN

Company Profile LIVN

Business Description

U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management segment. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.

20 Eastbourne Terrace
London, W2 6LG, GBR
Industry Medical Devices
Employees 3,000

Related Articles LIVN

FAQs for LivaNova PLC Stock

No. LIVN does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

LIVN’s market cap is 3.01 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

LIVN’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

LIVN’s price/sales is 2.89.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

LIVN’s price/forward earnings is 25.19.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

LIVN’s price/book is 2.57.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See LIVN’s valuation ratios compared to the Market Index.

LIVN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare LIVN’s historical performance against its industry peers and the overall market.